(Q36773464)

16 August 2017

title

Drug insight: role of the androgen receptor in the development and progression of prostate cancer (English)

1 reference

16 August 2017

1 reference

1

Mary-Ellen Taplin

1 reference

16 August 2017

language of work or name

1 reference

1 April 2007

1 reference

Nature Clinical Practice Oncology

16 August 2017

published in

1 reference

16 August 2017

volume

4

1 reference

16 August 2017

issue

4

1 reference

16 August 2017

page(s)

236-244

1 reference

Androgen receptor expression in human tissues: an immunohistochemical study

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

Novel biological agents for the treatment of hormone-refractory prostate cancer (HRPC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

Triplet repeat mutations in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Androgen resistance--the clinical and molecular spectrum

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

The steroid and thyroid hormone receptor superfamily

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Hormone-induced dissociation of the androgen receptor-heat-shock protein complex: use of a new monoclonal antibody to distinguish transformed from nontransformed receptors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Regulation of androgen receptor signaling in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Formation of the androgen receptor transcription complex

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Androgen receptor-cofactor interactions as targets for new drug discovery

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Identification and validation of novel androgen-regulated genes in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Human androgen receptor expression in prostate cancer following androgen ablation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

The CAG repeat within the androgen receptor gene and its relationship to prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Androgen Receptor Gene Amplification and Protein Expression in Recurrent Prostate Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

In vivo amplification of the androgen receptor gene and progression of human prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

ANDROGEN RECEPTOR GENE AMPLIFICATION AT PRIMARY PROGRESSION PREDICTS RESPONSE TO COMBINED ANDROGEN BLOCKADE AS SECOND LINE THERAPY FOR ADVANCED PROSTATE CANCER

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

The androgen receptor gene mutations database (ARDB): 2004 update

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Molecular biology of the androgen receptor

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Constitutive activation of the androgen receptor by a point mutation in the hinge region: a new mechanism for androgen-independent growth in prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Co-activator and co-repressor interplay on the human androgen receptor

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Androgen receptor signaling in androgen-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Molecular basis for interactions of G protein betagamma subunits with effectors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Androgen receptor activation by G(s) signaling in prostate cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Is dehydroepiandrosterone a hormone?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

The androgen axis in recurrent prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Current Status of Bilateral Adrenalectomy or Advanced Prostatic Carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

The regulation of 17,20 lyase activity

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

The influence of finasteride on the development of prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Casodex: preclinical studies and controversies

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Structural basis for antagonism and resistance of bicalutamide in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Development of peptide antagonists for the androgen receptor using combinatorial peptide phage display

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Hsp90 as a therapeutic target in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Transition metal complexes of cyclic and open ozone and thiozone

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Disruption of gene expression and induction of apoptosis in prostate cancer cells by a DNA-damaging agent tethered to an androgen receptor ligand

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0765

7 January 2021

Identifiers

DOI

10.1038/NCPONC0765

1 reference

16 August 2017

1 reference